Chimerix (CMRX) to Release Quarterly Earnings on Thursday

by · The Cerbat Gem

Chimerix (NASDAQ:CMRX – Get Free Report) will issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Chimerix (NASDAQ:CMRX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, meeting the consensus estimate of ($0.23). The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $1.26 million. During the same quarter last year, the business posted ($0.21) EPS. On average, analysts expect Chimerix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Chimerix Stock Performance

Chimerix stock opened at $1.02 on Wednesday. The stock has a market cap of $91.43 million, a P/E ratio of -1.07 and a beta of 1.13. The firm’s fifty day moving average price is $0.90 and its 200-day moving average price is $0.91. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $1.30.

Wall Street Analysts Forecast Growth

CMRX has been the topic of a number of analyst reports. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research report on Wednesday, August 21st. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Chimerix in a research report on Wednesday, August 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a research report on Tuesday, August 13th.

Check Out Our Latest Stock Analysis on CMRX

Chimerix Company Profile

(Get Free Report)

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.

Featured Articles